Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT02231736 Recruiting - Cancer Clinical Trials

Chromosomal Damage in Type 2 Diabetes Patients (MIKRODIAB)

MIKRODIAB
Start date: May 2014
Phase: N/A
Study type: Observational

The purpose of the study is to determine whether glycemic control (HbA1c) is linked to chromosomal damage in type 2 Diabetes patients

NCT ID: NCT02228811 Terminated - Clinical trials for Metastatic Solid Tumors

A Study of DCC-2701 in Participants With Advanced Solid Tumors

Start date: June 2014
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.

NCT ID: NCT02224599 Terminated - Cancer Clinical Trials

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

Start date: July 28, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Patients diagnosed with progressive and/or refractory solid malignancies, who have failed conventional therapy, and have no available, potentially curative therapeutic options, will be candidates for this Phase I/II study. Following confirmation of disease progression and/or refractoriness, eligible patients who agree to participate and sign an informed consent form will have their tumor cells/tissues and/or blood analyzed for the expression of a specific panel of Tumor Associated Peptide Antigens (TAPAs), including Sp17, ropporin, AKAP-4, PTTG1, Span-xb, Her-2/neu, HM1.24, NY-ESO-1 and MAGE-1.

NCT ID: NCT02223312 Withdrawn - Cancer Clinical Trials

Therapy for Progressive and/or Refractory Hematologic Malignancies

Start date: July 28, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of Tumor Associated Peptide Antigen (TAPA) pulsed dendritic cell (DC) vaccines in the treatment of progressive and/or refractory hematologic malignancies (HM). We hypothesize that treatment of patients with relapsed and/or refractory HM, without available potentially curative treatment options, and whose neoplastic cells express at least one (1) TAPA of a defined panel of TAPAs, using low-dose cyclophosphamide (CYP) followed by an autologous, monocyte-derived, TAPA-pulsed DC vaccine and low-dose granulocyte macrophage colony stimulating factor (GM-CSF), will result in TAPA-specific T-cell responses without significant toxicities. We also hypothesize CD4+ T-cell and CD8+ T-cell responses generated against specific TAPAs may translate into clinical antitumor activity.

NCT ID: NCT02222844 Recruiting - Cancer Clinical Trials

Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers

IMPRESS
Start date: August 2014
Phase: N/A
Study type: Interventional

Patients with suspected or proven sigmoid colon adenocarcinoma, eligible for curative treatment whose MRI can be reviewed prior to surgery and has no decision regarding radical treatment are eligible. Patient are randomised to the control arm which the standard care of preoperative CT imaging and subsequent discussion by the Multidisciplinary Team or the interventional arm which has the additional use of MRI imaging and subsequent discussion by the Multidisciplinary Team. Patients are followed up at 1 and 3 years together with QoL questionnaires.

NCT ID: NCT02219269 Completed - Cancer Clinical Trials

A Complex Contraception Registry

Start date: June 2014
Phase: N/A
Study type: Observational [Patient Registry]

The investigators will conduct a prospective observational cohort study to investigate factors that influence contraceptive method utilization among women with medical conditions. The investigators will also investigate how women with medical conditions access to contraception and family planning fellowship trained specialist. After the baseline questionnaire, there be a 3 month and 6 month follow up questionnaire to investigate continuation and satisfaction with the contraceptive method. This study is unique because it will allow us to explore doing collaborative family planning research at the multiple UC medical campuses.

NCT ID: NCT02216773 Completed - Cancer Clinical Trials

Regeneration of Liver: Portal Vein Embolization Versus Radiofrequency Assisted Ligation for Liver Hypertrophy (REBIRTH)

REBIRTH
Start date: July 2015
Phase: N/A
Study type: Interventional

The aim of this study is to compare two different techniques (portal vein embolization and radiofrequency assisted liver partition with portal vein ligation) for increasing liver volume prior to major liver resection.

NCT ID: NCT02213432 Terminated - Cancer Clinical Trials

Influenza Vaccination in Cancer Patients

Start date: September 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the timing of influenza vaccination to induce higher antibody response in adult patients with non-hematologic malignancies receiving scheduled cytotoxic chemotherapy.

NCT ID: NCT02212132 Completed - Cancer Clinical Trials

Relations Between Cognitive Complaints and Cognitive Scores Goals in Cancer: Assessment of Metamemory

Start date: April 2013
Phase: N/A
Study type: Observational

This pilot study is, in this new and original approach in cancer pathology, measure and explain the correspondence between perceived cognitive impairment (cognitive complaint) by cancer patients and their cognitive scores goals with tasks metamemory while controlling the anxiety and depression and fatigue factors of patients.

NCT ID: NCT02207543 Terminated - Cancer Clinical Trials

Assessment of Patient Satisfaction in Palliative Cancer When They Return Home After Hospitalization in Palliative Care

Start date: June 2014
Phase: N/A
Study type: Interventional

The proposed work is part of a multidisciplinary approach to continuity of care in the particular context of the palliative phase of cancer. In conducting this study, we would like to characterize, at the regional level, satisfaction with the care of patients and their families in their care home situations palliative cancer. This evaluation will be based on questionnaires adapted versions in French language satisfaction questionnaires recently validated for patients in palliative situation and supported home care. It will also identify the challenges faced by both patients, caregivers attending physicians. The evaluation of these elements is a prerequisite to propose ways of improving at a hospital palliative care for output relay and anticipate the coordination of care for optimal care of the patient at home, to meet the expectations of different stakeholders, or even prevent certain readmissions "avoidable".